This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Omnicell (OMCL) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Merit Medical (MMSI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Reasons Why SARTORIUS AG (SARTF) Is a Great Growth Stock
by Zacks Equity Research
SARTORIUS AG (SARTF) possesses solid growth attributes, which could help it handily outperform the market.
Earnings Estimates Rising for SARTORIUS AG (SARTF): Will It Gain?
by Zacks Equity Research
SARTORIUS AG (SARTF) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
What Makes SARTORIUS AG (SARTF) a New Buy Stock
by Zacks Equity Research
SARTORIUS AG (SARTF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SARTORIUS AG (SARTF) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
SARTORIUS AG (SARTF) delivered earnings and revenue surprises of 10.45% and 5.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
SARTORIUS AG (SARTF) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
SARTORIUS AG (SARTF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: National Vision Holdings, Maravai LifeSciences, Sonova Holding, Sartorius and Henry Schein
by Zacks Equity Research
The Zacks Analyst Blog Highlights: National Vision Holdings, Maravai LifeSciences, Sonova Holding, Sartorius and Henry Schein
5 MedTech Stocks to Gain in 2021 as Base Business Recovers
by Urmimala Biswas
These five MedTech stocks, EYE, MRVI, SONVY, SARTF and HSIC, all with a favorable Zacks Rank and growth parameters are expected to put up a robust performance in 2021.
Henry Schein (HSIC) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SARTORIUS AG (SARTF) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
SARTORIUS AG (SARTF) delivered earnings and revenue surprises of 10.84% and 6.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
SARTORIUS AG (SARTF) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
SARTORIUS AG (SARTF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has SARTORIUS (SARTF) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (SARTF) Outperforming Other Medical Stocks This Year?
SARTORIUS AG (SARTF) Misses Q3 Earnings Estimates
by Zacks Equity Research
SARTORIUS AG (SARTF) delivered earnings and revenue surprises of -7.78% and 4.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
HMS Holdings (HMSY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
HMS Holdings (HMSY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DexCom (DXCM) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SARTORIUS AG (SARTF) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
SARTORIUS AG (SARTF) delivered earnings and revenue surprises of 8.75% and 6.91%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
SARTORIUS AG (SARTF) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
SARTORIUS AG (SARTF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SARTORIUS AG (SARTF) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
SARTORIUS AG (SARTF) delivered earnings and revenue surprises of 24.62% and 12.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for April 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
SARTORIUS AG (SARTF) to Report Q1 Results: What to Know Ahead of the Release
by Zacks Equity Research
SARTORIUS AG (SARTF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medical Product's Q4 Earnings on Feb 24: VWR, SARTF, HMSY
by Zacks Equity Research
Let's take a look at the major Medical Product stocks slated to release their fourth-quarter 2016 numbers on Feb 24.